Previous Article | Next Article ![]()
Infection and Immunity, September 2000, p. 5462-5465, Vol. 68, No. 9
National Hansen's Disease Programs,
Laboratory Research Branch at Louisiana State University, Baton
Rouge, Louisiana,1 and St. Thomas
Hospital and Leprosy Centre, Chettupattu TS Dt 606 801 Tamil Nadu,
South India2
Received 2 December 1999/Returned for modification 14 February
2000/Accepted 5 June 2000
The manifestation of leprosy in humans is largely determined
by host immunity to Mycobacterium leprae and is a model for
immunoregulation in a human disease. However, animal models available
for exploration of the leprosy spectrum are inadequate. This
study explored M. leprae infection in mice deficient in
inducible nitric oxide synthase, and this report describes elements
resembling borderline tuberculoid leprosy in humans.
A major component of the
antimicrobial repertoire of effector mechanisms of activated
macrophages (M The use of the competitive inhibitor of L-arginine,
NG-monomethyl-L-arginine
(L-NMA), as well as other inhibitors of iNOS, including
aminoguanidine (AG), allowed in vitro demonstration that M The present studies employed iNOS KO mice to explore further the role
of RNI in host resistance to viable M. leprae freshly harvested from infected nu/nu mice (3). Figure
1 shows in vitro results obtained with B6
and iNOS KO peritoneal M
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Role of Inducible Nitric Oxide Synthase in
Resistance to Mycobacterium leprae in Mice
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
) is the production of reactive nitrogen intermediates
(RNI), chiefly nitric oxide, generated from L-arginine by a
high-output, cytokine-inducible isoform of the enzyme, inducible nitric
oxide synthase (iNOS). In murine models, RNI have been shown to be
necessary for the M
-mediated inhibition of tumor cells and a variety
of extracellular and intracellular pathogens (6, 17).
Evidence that RNI play a key antimicrobial role in human M
is less
direct but is accumulating (21).
RNI are
important in the gamma interferon (IFN-
)-activated M
killing of
Mycobacterium leprae (2) and M. tuberculosis (1, 8, 11). The inclusion of L-NMA or
AG in drinking water permitted in vivo demonstration of the
role of RNI in host resistance to M. bovis BCG
(15) and M. tuberculosis (7, 13),
respectively. Recently, gene knockout (KO) mice with a targeted
disruption in the calmodulin binding site of the iNOS gene (iNOS KO
mice) were developed which lack a functional iNOS (16).
These iNOS KO mice yielded IFN-
-treated M
incapable of coping
with M. tuberculosis (1). In vivo infection
with virulent M. tuberculosis was greatly exacerbated in
this and another strain of iNOS-deficient mice (1, 18).
where additional controls consisted
of B6 M
treated with the RNI inhibitors L-NMA and AG. Clearly,
activated iNOS KO M
or B6 M
treated with L-NMA or AG failed
to produce RNI and were unable to kill or inhibit M. leprae. Similar results were obtained with bone marrow-derived M
(not shown).

View larger version (28K):
[in a new window]
FIG. 1.
Effects of activated peritoneal M
from B6 and iNOS KO
mice on M. leprae. (A) Viability of M. leprae
recovered from control (open bars) or
IFN-plus-lipopolysaccharide-activated (hatched bars) B6 M
incubated
in the presence or absence of 500 µM AG or 500 µM L-NMA and from
iNOS KO M
. Viability of bacilli was determined 48 h
postinfection by radiorespirometric measurement of the oxidation of
[14C]palmitic acid (19). (B) Nitrite levels in
the culture supernatants were determined using the Griess reagent.
Control versus activated M
: **, P < 0.01; ***,
P < 0.001.
Dietary inhibition of RNI production was not a feasible approach by
which to study the role of this antimicrobial mechanism of
resistance to leprosy in vivo because the protracted nature of
the mouse footpad model for infection with M. leprae
requires several months to demonstrate growth. Therefore,
M. leprae infection was carried out with iNOS KO
mice to determine if, as in the M. tuberculosis model, M
inability to cope with M. leprae infection in vitro is also
manifested in vivo by exacerbated infection. We employed the standard
Shepard mouse footpad assay (20), in which the number of
acid-fast bacilli (AFB) peaks at 4 to 6 months, plateaus for several
months, and then gradually falls off to the counting threshold. As
shown in Fig. 2, M. leprae
growth followed this typical pattern in control B6 mice over 18 months.
In iNOS KO mice, counts of AFB per footpad were generally higher at 3 and 6 months in one experiment and 11 months in a second experiment although statistical significance (Welch's t test) was
reached only at the 3-month time point (P < 0.05). More
noteworthy, considering the marked differences in granuloma
formation and histopathological responses (see below), were the
findings that the number of AFB per footpad fell off at the same rate
and to the same level in KO mice as in controls.
|
Clearly, growth of M. leprae was not greatly exacerbated in
iNOS KO mice. These results appear to contrast with findings obtained with experimental M. tuberculosis infections, in which the
absence of RNI was linked with the inability of activated M
to kill
in vitro coupled with exacerbated growth of the tubercle bacillus and
increased mouse mortality (1, 7, 8, 13, 18). Our
findings also contrast with reports in which iNOS-deficient mice
not only controlled M. avium growth in vivo but
also did so in vitro in activated M
(4, 5, 12, 14). Thus,
although the present studies appear to underscore the important
role of RNI in M
-mediated resistance to M. leprae, these findings also demonstrate that control of
M. leprae infection in vivo can be maintained in
the absence of this potent antimicrobial mechanism. An important
alternative antimicrobial pathway to be considered is the
production of reactive oxygen intermediates (ROI) by M
. We
have shown, however, that M
from iNOS KO mice are not
deficient in the production of ROI (1) but, in the
absence of RNI, ROI alone is not sufficient to kill either M. tuberculosis or M. leprae.
Control of M. leprae growth in iNOS-deficient mice may
involve a more complicated compensatory consequence of the
microenvironmental conditions associated with granuloma formation. At
15 months in B6 mice, the granuloma which formed around an injected
bolus of M. leprae was confined to a small area in the
footpad immediately underneath the epidermis (Fig.
3A) and consisted of small focal collections of M
, a few epithelioid cells, and lymphocytes which were collected around neurovascular bundles. The inflammation did
not invade nerves or muscles. There were minimal superficial extensions
along the tissue spaces between muscle bundles. Acid-fast staining (not
shown) revealed a few clumps of bacilli inside M
, especially in
those found immediately beneath the epidermis. In marked contrast, the
granulomatous inflammation of the iNOS KO footpad was over 10 times the
size of the granuloma found in the control mice (Fig. 3B). The
granuloma was distributed over an area underneath the epidermis, around
neurovascular bundles, and was spread along the tissue spaces between
muscle bundles, even reaching the bones. The granuloma was confluent
and organized and was composed of numerous epithelioid cells, a few
M
, and dense collections of lymphocytes (Fig. 3C). In areas, the
granuloma infiltrated the muscle bundles, partly destroying them (Fig.
3D), and also infiltrated the perineurium. Acid-fast staining (not shown) revealed clumps of bacilli inside M
mainly in the
middle of the granuloma. Thus, granuloma formation in iNOS KO mice was ultimately associated with destruction of M. leprae and
persisting organisms continued to evoke a granulomatous response. Two
recent studies (12, 14) have shown enhanced granuloma
formation in M. avium-infected mice when
production of RNI was inhibited by either gene disruption or
chemical inhibition, and this response was attributed to
modulation of cytokine production. Ongoing
immunohistopathological studies and evaluation of local cytokine
profiles in our M. leprae-infected mouse footpad model may
shed further light on these compensatory mechanisms of resistance.
|
Finally, it is noteworthy that our findings appear to share attributes with an important form of human leprosy. Overall, the histological picture seen in iNOS KO mice was one resembling human borderline tuberculoid leprosy. The broad clinical-immunopathological spectrum of leprosy represents a fascinating example of immunoregulation in a chronic, nonfatal human infectious disease. But current murine models of experimental leprosy generally represent only the polar forms of the disease: tuberculoid leprosy with limited growth in the footpads of conventional, immunocompetent mice and lepromatous leprosy in which growth is largely unrestricted in the footpads of athymic nu/nu mice (9, 10). The borderline area of the clinical-immunopathological manifestations of leprosy is by far the most intriguing to immunologists. Unlike the tuberculoid and lepromatous forms, the borderline form is unstable and may downgrade and evolve into a more lepromatous disease or upgrade into a more tuberculoid disease, often with the appearance of a "reversal reaction" resulting from the onset of enhanced cell-mediated immunity with damaging consequences for surrounding nerves.
In humans, understanding the mechanisms and prevention of reversal reactions is one of the main goals of leprosy research. The development of strains of mice with targeted gene disruptions has opened up the possibility of exploring models more representative of the human leprosy spectrum. As the M. leprae-infected footpad lesions of iNOS KO mice appear to resemble borderline tuberculoid lesions, the present findings may be exploitable as a model for understanding the instability of borderline disease. Experiments are under way to determine the host response to larger numbers of M. leprae organisms and explore the possibility of further manipulation of the cell-mediated immune system in infected iNOS KO mice.
| |
ACKNOWLEDGMENTS |
|---|
We thank Nashone Soileau, J. P. Pasqua, Julie Loesch, Angelina Deming, and Greg McCormick for technical assistance and Penne Cason for clerical help.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: National Hansen's Disease Programs, Laboratory Research Branch at Louisiana State University, P.O. Box 25072, Baton Rouge, LA 70894. Phone: (225) 346-5764. Fax: (225) 346-5786. E-mail: ladams1{at}lsu.edu.
Editor: S. H. E. Kaufmann
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Adams, L. B., M. C. Dinauer, D. E. Morgenstern, and J. L. Krahenbuhl. 1997. Comparison of the roles of reactive oxygen and nitrogen intermediates in the host response to Mycobacterium tuberculosis using transgenic mice. Tubercle Lung Dis. 78:237-246[CrossRef][Medline]. |
| 2. | Adams, L. B., S. G. Franzblau, Z. Vavrin, J. B. Hibbs, Jr., and J. L. Krahenbuhl. 1991. L-Arginine-dependent macrophage effector functions inhibit metabolic activity of Mycobacterium leprae. J. Immunol. 147:1642-1646[Abstract]. |
| 3. | Adams, L. B., N. A. Soileau, J. R. Battista, and J. L. Krahenbuhl. 2000. Inhibition of metabolism and growth of Mycobacterium leprae by gamma-irradiation. Int. J. Lepr. 68:1-10. |
| 4. | Appelberg, R., and I. M. Orme. 1993. Effector mechanisms involved in cytokine-mediated bacteriostasis of Mycobacterium avium infection in murine macrophages. Immunology 80:352-359[Medline]. |
| 5. | Bermudez, L. E. 1993. Differential mechanisms of intracellular killing of Mycobacterium avium and Listeria monocytogenes by activated human and murine macrophages. The role of nitric oxide. Clin. Exp. Immunol. 91:277-281[Medline]. |
| 6. | Bogdan, C., M. Rollinghoff, and A. Diefenbach. 2000. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr. Opin. Immunol. 12:64-76[CrossRef][Medline]. |
| 7. | Chan, J., K. Tanaka, D. Carroll, J. Flynn, and B. R. Bloom. 1995. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect. Immun. 63:736-740[Abstract]. |
| 8. |
Chan, J.,
Y. Xing,
R. S. Magliozzo, and B. R. Bloom.
1992.
Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages.
J. Exp. Med.
175:1111-1122 |
| 9. | Chehl, S., J. Ruby, C. K. Job, and R. C. Hastings. 1983. The growth of Mycobacterium leprae in nude mice. Lepr. Rev. 54:283-304[Medline]. |
| 10. | Colston, M. J., and G. R. Hilson. 1976. Growth of Mycobacterium leprae and M. marinum in congenitally athymic (nude) mice. Nature 262:736-741. |
| 11. | Denis, M. 1991. Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. Cell. Immunol. 132:150-157[CrossRef][Medline]. |
| 12. | Ehlers, S., S. Kutsch, J. Benini, A. Cooper, C. Hahn, J. Gerdes, I. Orme, C. Martin, and E. T. Rietschel. 1999. NOS2-derived nitric oxide regulates the size, quantity and quality of granuloma formation in Mycobacterium avium-infected mice without affecting bacterial loads. Immunology 98:313-323[CrossRef][Medline]. |
| 13. |
Flynn, J. L.,
C. A. Scanga,
K. E. Tanaka, and J. Chan.
1998.
Effects of aminoguanidine on latent murine tuberculosis.
J. Immunol.
160:1796-1803 |
| 14. |
Gomes, M. S.,
M. Florido,
T. F. Pais, and R. Appelberg.
1999.
Improved clearance of Mycobacterium avium upon disruption of the inducible nitric oxide synthase gene.
J. Immunol.
162:6734-6739 |
| 15. | Granger, D. L., J. B. Hibbs, Jr., and L. M. Broadnax. 1991. Urinary nitrate excretion in relation to murine macrophage activation. Influence of dietary L-arginine and oral NG-monomethyl-L-arginine. J. Immunol. 146:1294-1302[Abstract]. |
| 16. |
Laubach, V. E.,
E. G. Shesely,
O. Smithies, and P. A. Sherman.
1995.
Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death.
Proc. Natl. Acad. Sci. USA
92:10688-10692 |
| 17. | MacMicking, J., Q. Xie, and C. Nathan. 1997. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15:323-350[CrossRef][Medline]. |
| 18. |
MacMicking, J. D.,
R. J. North,
R. LaCourse,
J. S. Mudgett,
S. K. Shah, and C. F. Nathan.
1997.
Identification of nitric oxide synthase as a protective locus against tuberculosis.
Proc. Natl. Acad. Sci. USA
94:5243-5248 |
| 19. |
Ramasesh, N.,
L. B. Adams,
S. G. Franzblau, and J. L. Krahenbuhl.
1991.
Effects of activated macrophages on Mycobacterium leprae.
Infect. Immun.
59:2864-2869 |
| 20. | Shepard, C. C., and D. H. McRae. 1968. A method for counting acid-fast bacteria. Int. J. Lepr. 36:78-82. |
| 21. | Weinberg, J. B. 1998. Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Mol. Med. 4:557-591[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»